AbbVie, o se kamupani su'esu'e i le lalolagi atoa biopharmaceutical, na fa'ailoa mai ua fa'atagaina e le Health Canada le SKYRIZI® (risankizumab), mo le togafitia o tagata matutua e maua i le ma'i gugu psoriatic. I le PsA, e mafai ona fa'aogaina le SKYRIZI na'o ia pe fa'atasi ma se fa'ama'i fa'ama'i-e suia fa'ama'i (cDMARD) (eg, methotrexate).
“O le mauaina e SKYRIZI o le Fa'asilasilaga o le Tausi mo le togafitia o le gasegase oona o le psoriatic e maua ai le fa'amoemoega fa'aopoopo i tagata mama'i. O taunuʻuga mai le Vaega 3 polokalame faʻataʻitaʻiga faʻapitoa e faʻaalia ai le faʻaleleia atili o faʻailoga ma faʻamaoniga e fesoʻotaʻi ma lenei faʻamaʻi, "o le tala lea a Dr. Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Probity Medical Research.
"I AbbVie, matou te taumafai e suia le tulaga o le tausiga mo tagata immunocompromised, ma matou te fiafia i le faamaoniga a le Health Canada o SKYRIZI mo le togafitia o tagata matutua e maua i le maʻi gugu o le psoriatic," o le tala lea a Tracey Ramsay, Sui Peresetene ma Pule Sili, AbbVie Canada.
Ole fa'ailoga lona lua lea mo SKYRIZI ile Kanata. Ia Aperila 2019, na faʻamaonia ai e le Soifua Maloloina Kanata le SKYRIZI mo le togafitia o tagata matutua mamaʻi maʻi maʻi maʻi ma ogaoga psoriasis plaque o loʻo avea ma sui mo togafitiga faʻapitoa poʻo phototherapy.
OA MEA E AVEA MAI LENEI TUSI:
- “At AbbVie, we strive to transform the standard of care for immunocompromised people, and we are excited with Health Canada’s approval of SKYRIZI for the treatment of adults with active psoriatic arthritis,”.
- In April 2019, Health Canada approved SKYRIZI for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- In PsA, SKYRIZI can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.
